ERBB2 and breast neoplasm: They also revealed that cytoplasmic and/or nuclear localization of the protein is significantly associated with an adverse outcome in each breast tumor molecular subtype, including HER2+, confirming the role of nuclear β-catenin in malignancy of breast tumor cells.